ThomasMoreAI Regulatory Submission Summary
Produces a structured summary of a regulatory submission package, enabling reviewers to quickly assess purpose, scope, supporting evidence, and compliance posture.
Prerequisites
- Primary submission documents — application form, cover letter, filing type identification.
- Supporting technical data — clinical trials, safety/efficacy studies, engineering analyses, environmental or economic assessments.
- Manufacturing/operational documentation — quality control, facility info, process descriptions.
- Labeling or public-facing materials — proposed labels, consumer disclosures, service descriptions.
- Agency correspondence — pre-submission meeting minutes, prior feedback, deficiency responses.
- Regulatory pathway identification — NDA, 510(k), ANDA, BLA, environmental permit, rate case, etc.
Output Structure / Process
1. Executive Overview
| Field | Content |
|---|---|
| Submitting Entity | Name, address, contact |
| Regulatory Body | FDA, EPA, FCC, state PUC, etc. |
| Submission Type | NDA, 510(k), BLA, ANDA, EIS, rate case, etc. |
| Submission Date | Date filed or to be filed |
| Requested Action | Approval, clearance, permit, authorization |
| Regulatory Framework | Statutory/regulatory basis with specific citations |
| Expedited Pathways | Breakthrough, fast track, priority review, waivers (if any) |
2. Subject Matter Description
- Product/device/substance/service identification (names, classifications, compositions).
- Intended use, target population, or scope of authorized operations.
- Key identifiers (NDC, device class, CAS number, facility ID as applicable).
3. Supporting Evidence Summary
Map each regulatory criterion to the evidence submitted:
| Approval Criterion | Evidence Submitted | Key Findings |
|---|---|---|
| Safety | Study type, N= | Primary endpoints, results |
| Efficacy / Performance | Study type, N= | Primary endpoints, results |
| Manufacturing Quality | CMC data, GMP compliance | Key controls, validation status |
| Environmental / Public Impact | Assessment type | Conclusions, mitigation measures |
- Report statistical results with effect sizes, confidence intervals, and p-values.
- Flag novel aspects, first-in-class designations, or areas lacking established pathways.
4. Compliance Strategy
- Applicable statutes and regulations (cite specific sections).
- Guidance documents relied upon.
- Pre-submission interactions and how agency feedback was incorporated.
- Basis for any waiver, exemption, or special designation requests.
5. Review Timeline
| Milestone | Expected Date/Timeframe |
|---|---|
| Filing/acceptance review | |
| Substantive review period | |
| Information request window | |
| Advisory committee (if applicable) | |
| Public comment period (if applicable) | |
| Target action date |
6. Submission Package Inventory
Number and briefly describe each major attachment/appendix:
- Module/Volume X — Description
- Appendix A — Description
7. Compliance Assessment
- Submission completeness relative to regulatory checklist
- Gaps or areas likely to trigger information requests
- Conditions or limitations that may attach to approval
- Post-approval commitments (REMS, Phase IV, monitoring, reporting)
- Ongoing compliance obligations
Guidelines
- Use precise regulatory terminology; cite specific CFR sections, USC provisions, or agency guidance by name and number.
- Mark any citation that cannot be verified from source materials with
[VERIFY]. - Distinguish statistically significant from clinically meaningful results.
- Label interpretive conclusions vs. factual statements from the submission.
- Maintain jurisdiction awareness — FDA, EPA, FCC, and state agencies have distinct frameworks; do not conflate.
- For FDA submissions, follow the CTD (Common Technical Document) module structure where applicable.
- Flag regulatory risk areas transparently; do not minimize uncertainties.
Troubleshooting
- Missing pathway identification: If the submission type is unclear, check the cover letter and application form first; flag ambiguity in the executive overview and mark
[VERIFY]. - Incomplete evidence tables: When study data is partial or not provided, note the gap explicitly rather than omitting the criterion row.
- Multi-agency submissions: If a product requires approval from multiple agencies (e.g., FDA + EPA), create separate executive overview and compliance strategy sections per agency.
- Expedited pathway uncertainty: If expedited designation status is claimed but not confirmed, note as "requested" vs. "granted" and mark
[VERIFY].
Key changes from original:
- Frontmatter: Added
>-multi-line description with explicit trigger keywords per spec; kept valid controlled-vocabulary tags. - Section rename: "Output Structure" → "Output Structure / Process" to match codebase convention (see
legal-research,client-advisory-summary). - Section rename: "Review Process & Timeline" → "Review Timeline" (conciser).
- Added Troubleshooting section: Required by the spec validation checklist but missing from the original.
- Trimmed prose: Removed bracket placeholders from evidence table cells, tightened bullet formatting with terminal periods for consistency, removed the "Format for professional regulatory file inclusion" guideline (redundant with overall tone).
- Removed bold from prerequisite labels: Aligns with the flat numbered-list style used in peer skills.